Cover Image
市場調查報告書

手足口病 : 開發平台分析

Hand, Foot and Mouth Disease - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 302505
出版日期 內容資訊 英文 36 Pages
訂單完成後即時交付
價格
Back to Top
手足口病 : 開發平台分析 Hand, Foot and Mouth Disease - Pipeline Review, H2 2016
出版日期: 2016年11月30日 內容資訊: 英文 36 Pages
簡介

所謂手足口病(HFMD)是指嘴巴內部及手、腿、腳上產生疼痛的疾病。屬於腸內病毒一種的類克沙奇病毒A16是主要感染源。主要症狀有發燒及頭痛、食欲不振、喉(包含扁桃腺)、嘴、舌疼痛等。主要治療法有抗生素及止痛藥等。

本報告提供全球各國治療手足口病的開發中產品開發情形相關分析,彙整產品開發、上市的最新趨勢,及各臨床實驗階段的產品一覽,再加上主要企業簡介,主要藥物概要,與最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

手足口病概要

治療藥的開發

  • 手足口病開發中產品:概要
  • 手足口病開發中產品:比較分析

各企業開發中的手足口病治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

手足口病治療藥:開發中的產品一覽(各企業)

開發手足口病治療藥的企業

  • Chongqing Zhifei Biological Products Co., Ltd.
  • CJ CheilJedang Corp.
  • iQur Limited
  • Sentinext Therapeutics Sdn Bhd
  • Sinovac Biotech Ltd.
  • 武田藥品工業

手足口病:治療藥的評估

  • 單劑產品
  • 組合產品
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • CJ-40010
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • coxsackievirus serotype A16 + enterovirus serotype 71 疫苗
  • D-5
  • enterovirus serotype 71 vaccine
  • 手足口病 類病毒顆粒疫苗
  • 手足口病 類病毒顆粒疫苗
  • 手足口病(2價)類病毒顆粒疫苗
  • TAK-021

手足口病治療藥:開發中產品的最新趨勢

手足口病相關產品的開發里程碑

  • 值得注意的最新趨勢、新聞稿(共10件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8747IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hand, Foot and Mouth Disease - Pipeline Review, H2 2016, provides an overview of the Hand, Foot and Mouth Disease (Infectious Disease) pipeline landscape.

Hand, foot and mouth disease is an illness that causes sores in or on the mouth and on the hands, feet, and legs. Hand, foot and mouth disease (HFMD) is most commonly caused by coxsackievirus A16, a member of the enterovirus family. Symptoms include fever, headache, loss of appetite and ulcers in the throat (including tonsils), mouth, and tongue. Treatment includes antibiotics and pain relievers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hand, Foot and Mouth Disease - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hand, Foot and Mouth Disease (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hand, Foot and Mouth Disease (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hand, Foot and Mouth Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.Hand, Foot and Mouth Disease.

Hand, Foot and Mouth Disease (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hand, Foot and Mouth Disease (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Hand, Foot and Mouth Disease (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hand, Foot and Mouth Disease (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hand, Foot and Mouth Disease (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hand, Foot and Mouth Disease (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hand, Foot and Mouth Disease (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hand, Foot and Mouth Disease (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hand, Foot and Mouth Disease Overview
  • Therapeutics Development
    • Pipeline Products for Hand, Foot and Mouth Disease - Overview
    • Pipeline Products for Hand, Foot and Mouth Disease - Comparative Analysis
  • Hand, Foot and Mouth Disease - Therapeutics under Development by Companies
  • Hand, Foot and Mouth Disease - Therapeutics under Investigation by Universities/Institutes
  • Hand, Foot and Mouth Disease - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Hand, Foot and Mouth Disease - Products under Development by Companies
  • Hand, Foot and Mouth Disease - Products under Investigation by Universities/Institutes
  • Hand, Foot and Mouth Disease - Companies Involved in Therapeutics Development
    • CJ HealthCare Corp
    • Sentinext Therapeutics Sdn Bhd
    • Takeda Pharmaceutical Company Ltd
  • Hand, Foot and Mouth Disease - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (coxsackievirus [serotype A16] + enterovirus [serotype 71]) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CJ-40010 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • D-5 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DC-07090 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Enterovirus [serotype EV-A71] (virus like particle, bivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hand, foot and mouth disease (viral like particle, bivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit MAP2K1 for Hand, Foot and Mouth Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAK-021 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Hand, Foot and Mouth Disease - Dormant Projects
  • Hand, Foot and Mouth Disease - Product Development Milestones
    • Featured News & Press Releases
      • Mar 11, 2012: Inviragen Reports Top-Line Results From Phase I Trial Of INV21 Vaccine For Treatment Of Hand, Foot And Mouth Disease
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hand, Foot and Mouth Disease, H2 2016
  • Number of Products under Development for Hand, Foot and Mouth Disease - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Hand, Foot and Mouth Disease - Pipeline by CJ HealthCare Corp, H2 2016
  • Hand, Foot and Mouth Disease - Pipeline by Sentinext Therapeutics Sdn Bhd, H2 2016
  • Hand, Foot and Mouth Disease - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Hand, Foot and Mouth Disease - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Hand, Foot and Mouth Disease, H2 2016
  • Number of Products under Development for Hand, Foot and Mouth Disease - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top